Intensity Therapeutics (INTS) announced that it has been granted a 180 calendar day extension from The Nasdaq Stock Market to regain compliance with the Nasdaq’s minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq, following the expiration of the initial 180 calendar day period to regain compliance on December 3, 2025, which was initially granted on June 6, 2025. The company now has until June 1, 2026 to meet the Minimum Bid Price Requirement set forth in Nasdaq Listing Rule 5550(a)(2).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INTS:
- Intensity Therapeutics Expands At-The-Market Offering
- Intensity Therapeutics Reports Q3 2025 Financial Results
- Intensity Therapeutics reports Q3 EPS (6c) vs. (25c) last year
- Intensity Therapeutics Enters Securities Purchase Agreement
- Intensity Therapeutics prices 5M shares at 80c in registered direct offering